Table 2.

Comparison of demographic and clinical characteristics between the group with venous irritation and the group without venous irritation

Variable		Group with venous irritation (n = 24)	Group without venous irritation (n = 39)	p-value
Age, years	Median (range)	64 (35–73)	65 (39–84)	0.514^b
Sex (%)	Male	14 (58.3)	27 (69.2)	0.423^c
Sex (%)	Female	10 (41.7)	12 (30.8)	0.423^c
Body surface area, m²	Mean ± SD	1.60 ^a ± 0.14	1.68 ^a ± 0.16	0.035^d
Body mass index, n (%)	≥ 25	3 (12.5)	9 (23.1)	0.345^c
Body mass index, n (%)	< 25	21 (87.5)	30 (76.9)	0.345^c
Regimen (%)	Single	4 (16.7)	8 (20.5)	1^c
Regimen (%)	Combination	20 (83.3)	31 (79.5)	1^c
CDDP administration	Yes	18 (75.0)	27 (69.2)	0.776^c
CDDP administration	No	6 (25.0)	12 (30.8)	0.776^c
Department (%)	Respiratory medicine	7 (29.2)	19 (48.7)	0.188^c
Department (%)	Surgery	17 (70.8)	20 (51.3)	0.188^c
VNR dose, mg (%)	≥ 40	6 (25.0)	15 (38.5)	0.410^c
VNR dose, mg (%)	< 40	18 (75.0)	24 (61.5)	0.410^c
Route of administration (%)	Side port	6 (25.0)	13 (33.3)	0.578^c
Route of administration (%)	Main route	18 (75.0)	26 (66.7)	0.578^c
Drug formulation (%)	Branded	18 (75.0)	34 (87.2)	0.307^c
Drug formulation (%)	Generic	6 (25.0)	5 (12.8)	0.307^c
History of diabetes mellitus (%)	Yes	4 (16.7)	6 (15.4)	1^c
History of diabetes mellitus (%)	No	20 (83.3)	33 (84.6)	1^c
Dexamethasone premedication dose, mg	Mean ± SD	10.86 ± 3.00	10.92 ± 3.04	0.946 ^d
Hot compress with hot towel (%)	Yes	8 (33.3)	6 (15.4)	0.124 ^c
Hot compress with hot towel (%)	No	16 (66.7)	33 (84.6)	0.124 ^c

CDDP cisplatin, VNR vinorelbine. ^aDu Bois formula, ^bMann–Whitney U test, ^cFisher’s exact test, ^dStudent’s t-test